Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
28.84
+0.06 (0.21%)
At close: Oct 29, 2026, 4:00 PM EDT
28.20
-0.64 (-2.22%)
After-hours: Oct 29, 2026, 7:56 PM EDT
Beam Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Beam Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $49.38. The average 1-year stock price forecast is 71.22% higher than the current stock price, while the lowest is $26 (-9.85%) and the highest is $80 (+177.39%).
Price Target: $49.38 (+71.22%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Beam Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 12 | 12 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $78 → $79 | Buy | Reiterates | $78 → $79 | +173.93% | Oct 29, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $45 | Buy | Maintains | $45 | +56.03% | Oct 28, 2026 |
Unknown Analyst UBS No rating | UBS | Hold Maintains $28 | Hold | Maintains | $28 | -2.91% | Oct 28, 2026 |
| Citi | Citi | Buy Reiterates $68 | Buy | Reiterates | $68 | +135.78% | Oct 28, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $43 | Buy | Maintains | $43 | +49.10% | Oct 28, 2026 |
Financial Forecast
Revenue This Year
53.22M
from 139.74M
Decreased by -61.92%
Revenue Next Year
60.92M
from 53.22M
Increased by 14.48%
EPS This Year
-4.46
from -0.81
EPS Next Year
-4.75
from -4.46
EPS and Forward PE are based on non-GAAP adjusted numbers.